Safety assessment of Fe-dihydromyricetin (DMY) nano-coordinated polymer particles (NCPs) in vitro. Hematoxylin and eosin (HE) stained sections of heart, liver, spleen, lung, kidney, and brain from different groups of rats after 14 weeks of continuous treatment. DC + Fe-DMY (high): diabetic retinopathy (DR) control (DC) group treated with high-dose Fe-DMY NCPs (60 mg/kg). DC + Fe-DMY (low): DC group treated with low-dose Fe-DMY NCPs (10 mg/kg). NC: normal control group.